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Antibody  tests  are  useful  for mapping  the  distribution  of lymphatic  filariasis  (LF)  in  countries  and  regions
and for  monitoring  progress  in  elimination  programs  based  on mass  drug  administration  (MDA). Prior
antibody  tests  have  suffered  from  poor  sensitivity  and/or  specificity  or from  a  lack  of  standardization.  We
conducted  a multicenter  evaluation  of  a  new  commercial  ELISA  that  detects  IgG4  antibodies  to  the  recom-
binant  filarial  antigen  Bm14.  Four  laboratories  tested  a shared  panel  of  coded  serum  or plasma  samples
that  included  55  samples  from  people  with  microfilaremic  Wuchereria  bancrofti  or  Brugia  infections  and
26 control  samples.  Qualitative  results  were  identical  in  all four test  sites.  In  addition,  each  laboratory
tested  samples  from  their  own  serum  banks.  The  test  detected  antibodies  in  32  of  36  samples  (91%)
from  people  with  Brugian  filariasis  and in  96  of 98  samples  (98%)  from  people  with  Bancroftian  filariasis.
Specificity  testing  showed  that  many  serum  or plasma  samples  from  patients  with  other  filarial  infections
such  as  onchocerciasis  had  positive  antibody  tests.  Specificity  was  otherwise  excellent,  although  3 of  30
samples  from  patients  with  ascariasis  and  4 of  51 with  strongyloidiasis  had  positive  antibody  tests; it
is  likely  that  some  or all  of  these  people  had  previously  lived  in  filariasis-endemic  areas.  Antibody  test
results  obtained  with  eluates  from  blood  dried  on  filter  paper were  similar  to  those  obtained  with  plasma
tested  at  the  same  dilution.  This  test  may  be helpful  for diagnosing  LF  in  patients  with  clinical  signs  of
filariasis.  It may  also  be  a useful  tool  for use  in  LF  endemic  countries  to monitor  the  progress  of filariasis
elimination  programs  and  for  post-MDA  surveillance.. Introduction
Lymphatic filariasis (also known as elephantiasis; LF) is a dis-
bling and deforming disease that affects some 120 million people
n 83 countries; approximately 1.3 billion people are at risk of
ecoming infected with the nematode parasites (Wuchereria ban-
rofti and Brugia species) that cause this disease (Ottesen, 2006).
he Global Programme to Eliminate Lymphatic Filariasis (GPELF) is
sing mass drug administration (MDA) to reduce filarial infection
ates below those required for sustained transmission with the goal
f permanently eliminating LF in all endemic countries by the year
020 (Ottesen et al., 2008; World Health Organization, 2008). GPELF
elies on diagnostic tests to identify and map  LF-endemic areas
nd to monitor the impact of interventions such as MDA. A recent
eview discussed the value of different diagnostic tests (serum anti-
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001-706X/$ – see front matter ©  2010 Elsevier B.V. All rights reserved.
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gen and antibody assays and detection of parasite DNA in vector
mosquitoes) for different phases of LF elimination programs (Weil
and Ramzy, 2007).
In addition to their value as tools for diagnosing individual
patients, filarial antibody tests are useful for identifying endemic
areas and for following antibody rates in young children over time
as a means of assessing changes in transmission rates following
MDA (Ramzy et al., 2006; Weil et al., 2008). Several studies have
shown that an ELISA that detects IgG4 antibodies to the recombi-
nant filarial antigen Bm14 (GenBank accession number M95546.1,
also known as BmM14, similar to BmSXP-1, GenBank M98813) is
a sensitive marker for infections with B. malayi or W. bancrofti (or
for heavy exposure to these parasites) (Chandrashekar et al., 1994;
Ramzy et al., 1995; Lammie et al., 2004). Since antibodies to Bm14
clear very slowly after infected humans are treated (Helmy et al.,
2006), tests like the Bm14 ELISA are especially useful as tools for use
in serial surveys of young children to assess changes in LF transmis-
sion following MDA  (Ramzy et al., 2006; Weil and Ramzy, 2007).
Known limitations of the test are its cross-reactivity with serum
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Fig. 1. Relative sensitivity of the commercial and research laboratory filariasis anti-
body tests. The figure compares OD values obtained for 21 serum or plasma samples
from microfilaremic subjects with lymphatic filariasis by the Filariasis CELISA test20 G.J. Weil et al. / Acta Tr
r plasma samples from patients infected with other filarial par-
sites (e.g., Onchocerca volvulus and Loa Loa) and the fact that it
as a non-commercial, research grade test (Lammie et al., 2004).
 company has recently marketed an ELISA test kit based on Bm14
hat employs standardized reagents and an optimized protocol. The
urpose of this study was to conduct an independent, multicenter
rial to evaluate the performance of the commercial Bm14 antibody
est kit.
. Materials and methods
.1. Tests for antifilarial antibodies
The Filariasis CELISA Test (Cellabs, Brookvale, NSW, Australia)
s an indirect ELISA that detects IgG4 antibodies to the recombi-
ant B. malayi antigen Bm14. This test was performed according to
he protocol provided by the company with minor modifications.
riefly, serum or plasma and test control samples were tested in
uplicate at a dilution of 1:100. The positive kit control sample
as also tested at 1:1600 as a weak positive control. Incubation
imes for the serum or plasma and secondary antibody steps were
 h and 45 min, respectively. Reactions were stopped 15 min  after
ddition of substrate, and ELISA readers measured optical densities
n test wells at 450 nm.  Optical density (OD) values were blanked by
ubtracting OD values obtained with 100 l dH2O. For some analy-
es, we converted OD values to units to normalize results between
aboratories. Units were defined as the [(mean OD value for the
est sample minus the mean OD value for the kit negative control)
ivided by the (mean OD value for the kit positive control minus
he mean OD value for the kit negative control] × 100. Thus, units
epresent a measure of antibody activity in test samples relative
o the kit positive control value defined to contain 100 units. This
uantitation is only an approximation, because OD values are not
inearly related to antibody concentration.
The Washington University laboratory also tested serum sam-
les with a non-commercial ELISA for IgG4 antibodies to Bm14 (the
esearch laboratory Bm14 test), as previously described (Ramzy et
l., 1995).
.2. Definition of a positive test
Preliminary studies were performed at Washington University
o determine a cutoff for the ELISA test. The mean (SD) obtained
ith 20 non-endemic serum samples (St. Louis, USA) was 0.042
0.024). Thus, the mean OD plus 3 SD was 0.114. However, we
ecided to use a conservative cutoff for this study. Therefore, sam-
les that produced mean OD values of >0.250 were considered to
e positive for antibody reactivity.
.3. Elution of antibodies from dried blood samples
Venous blood was collected in EDTA from donors with no history
f exposure to LF. Thirty microliters aliquots of blood were cen-
rifuged, and 15 l of plasma was removed. We  then added 15 l
f test samples (serum or plasma) and resuspended the blood. Ten
icroliter aliquots of antibody-spiked blood samples were pipet-
ed onto round filter paper circles (TropBio, Townsville, Australia),
nd these were dried and stored at 5 ◦C until they were tested.
lution was performed by placing one blood spot in 500 l of the
it elution buffer in a 1.5 ml  tube overnight at 5 ◦C. Tubes were
entrifuged the next morning, and eluates (containing an approx-
mate 1:100 dilution of the test serum or plasma present in the
lood) were tested by ELISA in parallel with the same serum or
lasma samples used to spike the blood diluted 1:100 in sample
iluent.(gray bars) and the research laboratory Bm14 ELISA (black bars).
2.4. Serum sets and laboratories
The Washington University laboratory assembled a shared panel
of 81 de-identified and coded serum or plasma samples that was
tested blindly by the following four laboratories: Washington
University (WU), Bernhard Nocht Institute for Tropical Medicine,
Hamburg (BNI), Centers for Disease Control and Prevention (CDC),
and James Cook University (JCU). The shared panel included serum
samples from persons with Wuchereria bancrofti (n = 29), B. malayi
(n = 11), or B. timori (n = 15) microfilaremia from different coun-
tries (India, Indonesia, Sri Lanka, and Egypt), non-endemic samples
from residents of St. Louis, USA (n = 20), and samples from patients
with strongyloidiasis with no history of exposure to filariasis (n = 6).
These samples had been previously tested with the research ver-
sion of the Bm14 antibody test. Positive samples were selected to
represent a range of antibody reactivity. Laboratories were also
encouraged to test their own  panels of samples from persons with
filariasis (with microfilaremia or Mf)  and various types of control
sera. Dr. Thomas Nutman kindly provided samples obtained from
patients with ascariasis collected in an area of Ecuador that is non-
endemic for filariasis or onchocerciasis.
3. Results
3.1. Sensitivity of the Bm14 antibody test
Fig. 1 compares OD values obtained for 21 serum or plasma sam-
ples from patients with LF with the Filariasis CELISA test and the
research laboratory Bm14 test. These results show that the CELISA
test kit produced higher OD values than the research laboratory
test.
Antibody results obtained with the Filariasis CELISA test for dif-
ferent patient groups are shown in Fig. 2. Sensitivity was  evaluated
with Mf-positive filariasis serum or plasma samples from two study
laboratories (WU  and CDC). These included samples in the shared
panel and other samples from serum banks at these laboratories.
Thirty-two of 35 sera (91%) from people with B. malayi or B. tim-
ori infections had positive antibody tests. These sera were from
India and Indonesia. Ninety-six of 98 serum or plasma samples
(98%) from people with W.  bancrofti microfilaremia had positive
tests. These samples were from India, Egypt, Papua New Guinea,
Sri Lanka, Haiti, and Kenya. The difference in % positivity with
Brugia and Wuchereria samples was not statistically significant
(P = 0.22).
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Fig. 3. Antibody results obtained with serum or plasma samples and eluates from
dried blood samples. The figure compares optical densities (OD values) obtainedig. 2. Filariasis CELISA results (optical density) by serum or plasma category. Hor-
zontal lines show median values. The cutoff OD value of 0.250 is shown with a
ashed horizontal line.
.2. Specificity of the Bm14 antibody test
Specificity results are also shown in Fig. 2. All 20 non-endemic
ormal serum or plasma samples in the shared panel were nega-
ive at all study sites; the range of OD values obtained in different
aboratories for individual control samples in the shared panel was
0.014 to 0.135. The mean OD plus 3 SD obtained with the panel
f negative samples in the 4 test laboratories ranged from 0.082 to
.164.
All six samples in the shared panel from patients with strongy-
oidiasis were negative at all study sites. Two of 19 samples tested
t CDC from Brazilian patients with strongyloidiasis were weakly
ositive in the Bm14 test with OD values of 0.271 and 0.654. One of
9 samples from patients with strongyloidiasis tested at the JCU lab
as positive with an OD value of 0.711. One of 7 samples from expa-
riate patients with strongyloidiasis tested at BNI was  positive with
n OD of 0.262. Thus, 4 of 51 samples from patients with strongy-
oidiasis had positive Bm14 antibody tests (specificity 92.2%). It is
ossible that some or all of the patients with positive tests had been
xposed to filarial infections in the past. One of 25 samples submit-
ed to CDC for Strongyloides serology (data not shown in Fig. 2) was
ositive by the Bm14 test with an OD value of 1.939. This person had
reviously lived in Liberia and Ghana and may  have been exposed
o filarial infections.
Five of 5 samples from patients with ascariasis tested at CDC
ere negative with OD values < 0.1. Three of 15 samples from Turk-
sh patients with ascariasis tested at BNI were positive with OD
alues of 0.289–0.440. Travel histories were not available for these
atients. None of 10 Ecuadoran samples from patients with ascari-
sis tested at WU were positive. None of 6 non-endemic (USA)
amples with rheumatoid factor titers ≥ 1:64 were positive.
The BNI laboratory reported that 19 of 25 samples (76%) from
nchocerciasis patients living in an area of Ghana without bancrof-
ian filariasis had positive antibody tests. Twenty-two of 24 samples
92%) from an area in Uganda that is highly endemic for Mansonella
erstans and M.  streptocerca had positive antibody tests. There is
ome onchocerciasis in this area but no W.  bancrofti. In contrast,
nly 3 of 12 M.  perstans samples from a different area in Uganda
ith low-level onchocerciasis endemicity had positive antibody
ests.
.3. Interlaboratory reproducibility
Qualitative results for the 81 samples in the shared serum
anel were identical in all four laboratories. OD values for filari-
sis samples varied between laboratories with a mean coefficient
f variation (CV) of 0.16 (SD 0.15); CV values for antibody units
ere similar (mean 0.15, SD 0.14).with the Filariasis CELISA with serum or plasma samples (gray bars) and filter paper
blood eluates (black) for filariasis serum or plasma samples (sample numbers 1–11)
and  control samples (12–16).
3.4. Antibody tests of blood dried on filter paper
OD values obtained with eluates from blood dried on filter paper
were similar to those obtained with serum (Fig. 3).
4. Discussion
The purpose of this study was to evaluate the performance of the
Filariasis CELISA antibody test kit. This was an independent evalua-
tion that was  not sponsored by the manufacturer, although Cellabs
did provide kits at no cost for the study. The exercise was strength-
ened by participation of 4 different laboratories in 3 continents.
The laboratories tested a shared panel of coded sera, and each lab-
oratory performed supplemental testing with samples in their own
collections.
The CELISA test has several advantages over the research lab-
oratory Bm14 ELISA. First, the kit is manufactured under GMP
conditions with standardized reagents. This should improve repro-
ducibility of the test. Secondly, the package insert from the
manufacturer states that the kit has a shelf life of 12 months if
it is stored at 5 ◦C. The research laboratory test is not a kit, and
its components do not have a shelf life rating. Finally, the Filaria-
sis CELISA kit is more sensitive than the research laboratory Bm14
test. This may  be due to optimized reagent concentrations or to
the fact that the kit uses a more reactive horseradish peroxidase
substrate than the research test (3,3′,5,5′-tetramethylbenzidine vs
o-phenylenediamine).
The Bm14 CELISA had high sensitivity with samples from peo-
ple infected with W.  bancrofti or Brugia species. This is consistent
with results previously reported for the research laboratory ver-
sion of the test (Chandrashekar et al., 1994; Ramzy et al., 1995;
Lammie et al., 2004). Specificity testing confirmed that the test is
often positive with samples from people with other filarial infec-
tions such as onchocerciasis. Results for samples from people in
two areas of Uganda who  had M. perstans infections were inconsis-
tent and inconclusive. It is possible that some of the positive tests
in these people were due to coinfection or exposure to other filar-
ial parasites. Most samples from patients with strongyloidiasis or
ascariasis were antibody negative, and we  cannot be sure that per-
sons with positive tests had not been exposed to filarial infections.
For example, sporadic cases of LF are still seen in southern Turkey
(Cengiz et al., 2006). Therefore, we doubt that intestinal nematode
infections are associated with positive Bm14 antibody tests.
The present study used a cutoff value of 0.25 for a positive test.
The kit protocol recommends using a cutoff of 0.4 for definite pos-
itives and retesting samples with OD values in an indeterminant
S opica
r
d
v
t
W
r
t
t
u
fi
1
t
b
d
s
s
A
s
i
f
P
i
s
f
s
l
a
“
a
a
p
c
t
a
o
D
l
tion with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua22 G.J. Weil et al. / Acta Tr
ange of 0.200–0.400. The higher cutoff would not have made much
ifference in this study; only one positive filariasis serum had an OD
alue between 0.250 and 0.400. Two stronglyoidiasis samples and
wo ascariasis samples had OD values in this indeterminant zone.
e  also analyzed the data based on antibody units to normalize
esults based on the net OD values obtained with the positive con-
rol on each plate. This did not affect our results. We  found that
he OD cutoff of 0.25 produced the same results as a cutoff of 10
nits; only one positive filariasis serum would have been reclassi-
ed as antibody negative with the higher cutoff values of OD 0.4 or
5 units. This sensitivity analysis is encouraging, because it shows
hat the test is robust and that the results were not affected much
y different cutoff values in this range.
Similar antibody test results were obtained with serum and with
ried filter paper blood samples. The ability to test filter paper blood
amples will improve the field utility of the test. However, this
tudy tested blood samples that were spiked with positive sera.
dditional studies are needed to directly compare blood and serum
amples from the same subjects and to test the stability of antibod-
es in dried blood samples stored under different conditions.
In conclusion, the Bm14 CELISA appears to be an excellent test
or the specific detection of antibody responses to filarial parasites.
hysicians may  find this test useful to support a diagnosis of filar-
asis in patients with a history of exposure to filariasis and clinical
igns of the disease. The antibody test was sensitive and specific
or filarial infections in this study. However, prior studies have
hown that antifilarial antibodies are common in healthy people
iving LF-endemic areas who have negative tests for microfilaremia
nd filarial antigenemia and no clinical signs of filariasis (so-called
endemic normals”) (Weil et al., 1996). This high sensitivity makes
ntibody testing especially useful as an epidemiological tool for
ssessing levels of infection and/or exposure to filarial parasites in
opulations. This test has attractive features for use in LF endemic
ountries, namely robustness, high throughput, and the ability to
est filter paper blood samples. These features should help to make
ntibody monitoring a practical monitoring option for late stages
f filariasis elimination programs and for post-MDA surveillance.isclosure
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